Filtered By:
Drug: Insulin
Procedure: Heart Transplant

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 18 results found since Jan 2013.

Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research
Conclusion The high prevalence of comorbidities in patients with stroke indicates the need for therapies in preclinical studies that take into account these comorbidities in order to avoid failures in translation to the patient. Preclinical studies are beginning to evaluate the efficacy of MSC treatment in stroke associated with comorbidities, especially hypertension, for ischemic and hemorrhagic stroke. Regarding aging and diabetes, only ischemic stroke studies have been performed. For the moment, few studies have been performed and contradictory results are being reported. These contradictory results may be due to the u...
Source: Frontiers in Neurology - April 8, 2019 Category: Neurology Source Type: research

Medtronic and Viz.ai Look to Improve Stroke Outcomes with New Alliance
A collaboration between Viz.ai and Medtronic could lead to better outcomes for stroke patients. Through the distribution agreement, San Francisco, CA-based Viz.ai would increase the reach of its artificial intelligence solution for stroke. Viz.ai’s solution identifies suspected large vessel occlusion (LVO) strokes and automatically notify specialists. It could lead patients to get treatment by technologies like Dublin-based Medtronic’s Solitaire revascularization device. “By combining AI software with therapy that works, that’s how we can truly improve...
Source: MDDI - July 23, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Software Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Pre-treatment clinical assessment in head and neck cancer: United Kingdom National Multidisciplinary Guidelines.
Authors: Robson A, Sturman J, Williamson P, Conboy P, Penney S, Wood H Abstract This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. This paper provides recommendations on the pre-treatment clinical assessment of patients presenting with head and neck cancer. Recommendations • Comorbidity data should be collected as it is important in the analysis of survival, quality of life and functional outcomes after treatment as well as for comparing results of different treatment regimens and different centres. (R) • Patients with hypertens...
Source: Journal of Laryngology and Otology - November 15, 2016 Category: ENT & OMF Tags: J Laryngol Otol Source Type: research

MassDevice.com +5 | The top 5 medtech stories for May 12, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Xtant Medical amends Orbimed credit line to $15m, taps restructuring advisors Xtant Medical said today that it amended its senior credit line with OrbiMed Advisors, saying it plans to use the $15 million facility to pay off the ...
Source: Mass Device - May 12, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Heart Transplant Outcomes in Patients With Pretransplant Diabetes Mellitus.
CONCLUSIONS: Heart transplant recipients with pretransplant diabetes fared just as well as patients without pretransplant diabetes in 7 of the 8 outcomes examined, except for the number of days hospitalized during the first 3 years after heart transplant. This study provides clinically important new information on the greater hospitalization time and the reasons for hospitalization during the first 3 years after heart transplant in patients with pretransplant diabetes. PMID: 29092871 [PubMed - in process]
Source: American Journal of Critical Care - November 1, 2017 Category: Nursing Authors: Jalowiec A, Grady KL, White-Williams C Tags: Am J Crit Care Source Type: research

Targeting Hexokinase II to mitochondria to modulate energy metabolism and reduce ischemia‐reperfusion injury in heart
Summary Mitochondrially‐bound hexokinase II (mtHKII) has long been known to confer cancer cells with their resilience against cell death. More recently, mtHKII has emerged as a powerful protector against cardiac cell death. mtHKII protects against IR injury in skeletal muscle and heart, attenuates cardiac hypertrophy and remodelling, and is one of the major end‐effectors through which ischemic preconditioning protects against myocardial ischemia‐reperfusion injury. Mechanisms of mtHKII cardioprotection against reperfusion injury entail the maintenance of regulated OMM permeability during ischemia and reperfusion resu...
Source: British Journal of Pharmacology - August 30, 2013 Category: Drugs & Pharmacology Authors: Rianne Nederlof, Otto Eerbeek, Markus W Hollmann, Richard Southworth, Coert J Zuurbier Tags: Review Article Source Type: research

Targeting hexokinase II to mitochondria to modulate energy metabolism and reduce ischaemia‐reperfusion injury in heart
This article is part of a themed issue on Mitochondrial Pharmacology: Energy, Injury & Beyond. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2014.171.issue‐8
Source: British Journal of Pharmacology - March 28, 2014 Category: Drugs & Pharmacology Authors: Rianne Nederlof, Otto Eerbeek, Markus W Hollmann, Richard Southworth, Coert J Zuurbier Tags: Review Source Type: research

The type of fat you eat matters!
By: JoAnn E. Manson, MD, DrPH, and Shari S. Bassuk, ScD Contributing Editors, Brigham and Women’s Hospital, Harvard Medical School If you saw last month’s news headlines declaring that saturated fat is no longer deemed harmful to your heart, you may be (understandably!) confused. After all, for years, clinicians and scientists have recommended reducing saturated fat for heart health. Is it time to rethink this advice? Hardly. Here’s the deal. The research that sparked the recent news splash was an analysis by Canadian researchers of up to a dozen long-term observational studies of diet that included a total of 90,000...
Source: New Harvard Health Information - September 22, 2015 Category: Consumer Health News Authors: Contributing Editors Tags: Health Healthy Eating Fats saturated fats unsaturated fats Source Type: news

Will Too Much Sleep Make You Fat?
In last week's article, you learned exactly how not getting enough sleep (less than about 7 hours per night), can cause fat gain, muscle loss and an inability to control the appetite, along with increased risk for a host of chronic diseases such as diabetes and obesity. But the solution is definitely not to begin sleeping as much as you possibly can. Oversleeping may seem like a good idea to fight off the fat gain that can accompany undersleeping, but it's been shown that sleeping in excess of 9 hours per night can be just as damaging to your sleep cycles and your waistline as not getting enough sleep, and in this article...
Source: Healthy Living - The Huffington Post - August 5, 2016 Category: Consumer Health News Source Type: news

Why Diet Soda Could Actually Prevent You From Losing Weight
Reaching for a diet soda may actually hinder weight loss efforts, a new study done in mice suggests. In experiments, researchers found that the artificial sweetener aspartame, which is found in some diet drinks, may contribute to the development of a condition called “metabolic syndrome,” which involves a cluster of symptoms, including high blood pressure, high cholesterol levels and a large waist size. People with metabolic syndrome face an increased risk of heart disease, stroke and diabetes. The researchers found how aspartame could be linked with metabolic syndrome: Aspartame may stop a key gut enzyme ...
Source: Healthy Living - The Huffington Post - December 7, 2016 Category: Consumer Health News Source Type: news

Does Diet Soda Cause Weight Gain?
This study shows quite nicely that non-caloric sweeteners can alter gut microbes in mice -- a change that has negative metabolic consequences -- and provides preliminary evidence that it can happen in humans too. Unexpected consequences To further appreciate how complicated our handling of diet soda can be, here's another little example: Our intestine (or bowel) is covered with cells that secrete hormones. These cells react to the presence and composition of food by secreting peptides such as glucagon-like peptide 1 (GLP-1), peptide YY (PYY) and cholecystokinin - these names are not important - that work on the brain, sig...
Source: Healthy Living - The Huffington Post - December 7, 2016 Category: Consumer Health News Source Type: news

Why Diet Soda Could Actually Prevent You From Losing Weight
Reaching for a diet soda may actually hinder weight loss efforts, a new study done in mice suggests. In experiments, researchers found that the artificial sweetener aspartame, which is found in some diet drinks, may contribute to the development of a condition called “metabolic syndrome,” which involves a cluster of symptoms, including high blood pressure, high cholesterol levels and a large waist size. People with metabolic syndrome face an increased risk of heart disease, stroke and diabetes. The researchers found how aspartame could be linked with metabolic syndrome: Aspartame may stop a key gut enzyme ...
Source: Science - The Huffington Post - December 7, 2016 Category: Science Source Type: news

Cochrane Priority Reviews List: December 2016 Update
Cochrane-wide prioritisation remains an important project, with over 140 priority reviews or updates have been published since it began in January 2015.The December 2016 revision of the Cochrane Priority Reviews List includes new titles from the Cochrane Airways, Anaesthesia, Dementia& Cognitive Improvement, ENT, Epilepsy, Gynaecological, Neuro-oncology and Orphan Cancers, Gynaecology& Fertility, Haematological Malignancies, Heart, Incontinence, Kidney& Transplant, Lung Cancer, Neuromuscular Disease, Oral Health, Skin, Stroke, and Urology Groups.The following titles on the list are open to new authors:Long-acti...
Source: Cochrane News and Events - December 14, 2016 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news

Impact of Active Antihyperglycemic Components as herbal therapy for Preventive Health Care Management of Diabetes.
Abstract Diabetes is a metabolic hyperglycemic condition that progressively develops, effect small and large sensory fibers in affected population. It has various complications as hypertension, coronary artery disease, stroke, blindness, kidney disease as well as peripheral neuropathy. Sulfonylureas, thiazolidinediones, metformin, biguanidine, acarbose and insulin are commonly used drugs by diabetic patients, but these all have certain side effects. Even metformin, that is known as the miracle drug for diabetes has been found to be associated with side effects, as during treatment it involves complications with ey...
Source: Current Molecular Medicine - February 19, 2019 Category: Molecular Biology Authors: Kashyap H, Gupta S, Bist R Tags: Curr Mol Med Source Type: research